Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
The current Biogen(BIIB) stock price is $206.63, with a market capitalization of 31.53B. The stock trades at a price-to-earnings (P/E) ratio of 35.74.
On 2026-08-06, Biogen(BIIB) stock moved within a range of $205.80 to $212.18. With shares now at $206.63, the stock is trading +0.4% above its intraday low and -2.6% below the session's peak.
Trading activity shows a volume of 807.98K, compared to an average daily volume of 1.16M.
The stock's 52-week range extends from a low of $127.00 to a high of $219.72.
The stock's 52-week range extends from a low of $127.00 to a high of $219.72.
BIIB News
...
Citi raised the firm’s price target on Biogen (BIIB) to $215 from $200 and keeps a Neutral rating on the shares. The firm updated models in the biotechnology sp...
Biogen Inc. has reported its second-quarter 2026 results, with revenue rising to US$2.74 billion from US$2.65 billion a year earlier while net income dropped sh...
Analyst ratings
64%
of 36 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.